A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB
Human Gene Therapy Clinical Development · 2015
DOI: 10.1089/hum.2015.132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy Clinical Development, 2015. Verfasst von Aaron S Meadows und 14 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Meadows, A. S., Duncan, F. J., Camboni, M., Waligura, K., Montgomery, C. L., Zaraspe, K., Naughton, B. J., Bremer, W. G., Shilling, C., Walker, C., Bolon, B., Flanigan, K., McBride, K. L., McCarty, D. M., & Fu, H. (2015). A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB. Human Gene Therapy Clinical Development. https://doi.org/10.1089/hum.2015.132
Vancouver
Meadows AS, Duncan FJ, Camboni M, Waligura K, Montgomery CL, Zaraspe K, et al. A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB. Human Gene Therapy Clinical Development. 2015. doi:10.1089/hum.2015.132
BibTeX
@article{Meadows2015,
author = {Meadows, Aaron S and Duncan, F Jason and Camboni, Marybeth and Waligura, Kathryn and Montgomery, Chrystal L and Zaraspe, Kimberly and Naughton, Bartholomew J and Bremer, William G and Shilling, Christopher and Walker, Christopher and Bolon, Brad and Flanigan, Kevin and McBride, Kim L and McCarty, Douglas M and Fu, Haiyan},
title = {A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB},
journal = {Human Gene Therapy Clinical Development},
year = {2015},
doi = {10.1089/hum.2015.132}
}
EUVIMED